SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

25 Oct 2024 Evaluate
The September 2024 quarter revenue stood at Rs. 4365.60 millions, up 6.55% as compared to Rs. 4097.10 millions during the corresponding quarter last year.A big loss of -76.15% reported for the quarter ended September 2024 to Rs. 281.00  millions from Rs. 1178.10 millions.The company reported a degrowth in operating Profit to 1484.40 millions from 1514.70 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 4365.60 4097.10 6.55 8932.50 8210.00 8.80 14867.06 13307.25 11.72
Other Income 58.10 69.80 -16.76 109.70 110.10 -0.36 348.28 172.64 101.74
PBIDT 1484.40 1514.70 -2.00 2769.80 3110.10 -10.94 4886.42 5223.78 -6.46
Interest 562.60 65.50 758.93 1124.30 133.90 739.66 574.20 208.10 175.93
PBDT 921.80 1449.20 -36.39 1645.50 2976.20 -44.71 4312.22 5015.68 -14.03
Depreciation 461.60 250.00 84.64 917.10 451.60 103.08 1023.89 646.57 58.36
PBT 460.20 1199.20 -61.62 728.40 2524.60 -71.15 3288.33 4369.11 -24.74
TAX 179.20 21.10 749.29 277.00 238.90 15.95 291.21 389.03 -25.14
Deferred Tax 91.40 -197.30 -146.33 142.30 -196.90 -172.27 -285.23 -375.93 -24.13
PAT 281.00 1178.10 -76.15 451.40 2285.70 -80.25 2997.12 3980.08 -24.70
Equity 136.10 136.00 0.07 136.10 136.00 0.07 136.03 135.99 0.03
PBIDTM(%) 34.00 36.97 -8.03 31.01 37.88 -18.15 32.87 39.26 -16.27

Eris Lifesciences Share Price

1392.80 41.50 (3.07%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×